Abstract
We read with interest the recent article by Flaherty et al1 published in Circulation Research . In the analysis of this retrospective, single-center study, patients were randomized into 2 groups, percutaneous left ventricular assist device (pLVAD) supported and unsupported undergoing high-risk percutaneous coronary intervention. All patients had severely reduced ejection fractions (<35%) and high-risk clinical features. Because acute kidney injury is quite common in this cohort, Impella 2.5 pLVAD support was independently associated with a significant reduction in the risk of …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
